Hemorrhagic manifestations, hematomas & skin necrosis at inj site, osteoporosis, thrombocytopenia, asymptomatic & reversible elevation of the platelet count, skin or systemic allergic reactions, elevation of transaminase levels, hyperkalemia, hypereosinophilia.
View ADR Monitoring Website